All In Biotech

NDA 020504 · Teva Branded Pharm

Microzide

Hydrochlorothiazide · Oral · Thiazide Diuretic

Last checked: Nov 19, 2026Latest source record: Aug 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Dec 27, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

450

138 Phase 3, 14 recruiting

FAERS reports

146,331

98,127 serious, 10,200 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 5, 2025.

INDICATIONS AND USAGE Hydrochlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. Unlike potassium sparing combination diuretic products, hydrochlorothiazide may be used in those patients in whom the development of hyperkalemia cannot be risked, including patients taking ACE inhibitors. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances this edema may cause extreme discomfort which is not relieved by rest. In these cases a short course of diuretics may provide relief and may be appropriate.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 27, 1996 Original approval · Type 3 - New Dosage Form
1 products under this application
  • MICROZIDE · HYDROCHLOROTHIAZIDE 12.5MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydrochlorothiazide" as an intervention, any sponsor and status, largest first.

All 450 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue10,470
  • nausea10,084
  • drug ineffective9,765
  • diarrhoea8,711
  • pain7,943
  • headache7,893
  • dyspnoea7,876
  • dizziness7,629
  • arthralgia6,349
  • off label use6,034
  • asthenia5,795
  • vomiting5,776

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,310
20053,022
20063,005
20072,864
20083,115
20093,900
20105,287
20115,369
20125,907
20134,812
20146,176
20158,039
20168,663
20177,780
201810,001
201910,143
20209,294
20218,945
20228,828
20238,058
20247,549
20257,754
20265,505

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Nov 19, 2025

    Microzide, Capsule, 12.5 mg (NDC 0591-0347-05). A business decision was made to discontinue manufacture of the drug.

  • To Be Discontinued · updated Nov 19, 2025

    Microzide, Capsule, 12.5 mg (NDC 0591-0347-01). A business decision was made to discontinue manufacture of the drug.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,366 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.